Analysts at William Blair assumed coverage on shares of NuCana PLC (NASDAQ:NCNA) in a research report issued to clients and investors on Monday, The Fly reports. The firm set an “outperform” rating on the stock.

Other research analysts also recently issued reports about the company. Cowen and Company assumed coverage on NuCana PLC in a report on Monday. They set an “outperform” rating on the stock. Jefferies Group LLC assumed coverage on NuCana PLC in a report on Monday. They set a “buy” rating on the stock. Finally, Citigroup Inc. assumed coverage on NuCana PLC in a report on Monday. They set a “buy” rating and a $23.00 price target on the stock.

Shares of NuCana PLC (NASDAQ NCNA) opened at 13.883 on Monday. The company’s market capitalization is $441.63 million. The stock’s 50 day moving average price is $16.06 and its 200-day moving average price is $16.06. NuCana PLC has a 1-year low of $13.05 and a 1-year high of $19.95.

ILLEGAL ACTIVITY NOTICE: This news story was posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/10/23/nucana-plc-ncna-now-covered-by-william-blair.html.

About NuCana PLC

NuCana PLC is a clinical-stage biopharmaceutical company. The Company is focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The Company utilizes its ProTide technology to develop medicines to overcome cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells.

The Fly

Receive News & Ratings for NuCana PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana PLC and related companies with MarketBeat.com's FREE daily email newsletter.